In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
The historical rank and industry rank for GlaxoSmithKline Pharmaceuticals's Net Current Asset Value or its related term are showing as below:
NSE:GLAXO'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 16.21 Med: 36.6 Max: 92.52
Current: 26.31
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of GlaxoSmithKline Pharmaceuticals was 92.52. The lowest was 16.21. And the median was 36.60.
NSE:GLAXO's Price-to-Net-Current-Asset-Value is ranked worse than 87.52% of 609
companies
in the Drug Manufacturers industry
Industry Median: 5.63
vs NSE:GLAXO: 26.31
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
GlaxoSmithKline Pharmaceuticals Net Current Asset Value Related Terms
GlaxoSmithKline Pharmaceuticals Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline Pharmaceuticals Net Current Asset Value Chart
NSE:GLAXO vs LLY, JNJ, ABBV: Net Current Asset Value Comparison
For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pharmaceuticals Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of ₹91.53 mean?
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a Net Current Asset Value of ₹91.53 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. This is 150% above median its historical median of 36.60. Over the past decade, GlaxoSmithKline Pharmaceuticals' Net Current Asset Value has ranged from 16.21 to 92.52. According to the industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #533 out of 609 companies in the Drug Manufacturers industry, placing it in the top 87.5%.
Is GlaxoSmithKline Pharmaceuticals' Net Current Asset Value too high?
GlaxoSmithKline Pharmaceuticals' current Net Current Asset Value of ₹91.53 is 150% above median its 10-year median of 36.60. Over the past 10 years, this metric has ranged from a low of 16.21 to a high of 92.52. Based on the distribution chart, GlaxoSmithKline Pharmaceuticals ranks #533 out of 609 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' Net Current Asset Value compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #533 out of 609 companies for Net Current Asset Value. This places GlaxoSmithKline Pharmaceuticals in the lower half of its industry. The industry median Net Current Asset Value is 5.63. Historically, GlaxoSmithKline Pharmaceuticals' own Net Current Asset Value has ranged from 16.21 to 92.52 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.63, based on 609 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pharmaceuticals's current Net Current Asset Value is ₹91.53, which is 150% above median its own 10-year median of 36.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,623.61, compared to a current price of ₹2,410.80 — trading 8.1% below its estimated fair value. The current Net Current Asset Value is ₹91.53, which is 150% above median its 10-year median of 36.60. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current Net Current Asset Value is ₹91.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹2,410.80 is trading 8.1% below its estimated GF Value™ of ₹2,623.61.
GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:GLAXO:
Net Current Asset Value: ₹91.53 (150% above median its 10-year median of 36.60)
GF Value™: ₹2,623.61 vs. price of ₹2,410.80 (8.1% below fair value)
No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pharmaceuticals Business Description
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
73GF Score
Get the complete analysis for NSE:GLAXO
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAXO has been successfully added to your 
